Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
about
Nintedanib in NSCLC: evidence to date and place in therapyMolecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomaPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.A novel classification of lung cancer into molecular subtypesDetecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.Recent advances in personalized lung cancer medicineTargeting ErbB3: the New RTK(id) on the Prostate Cancer Block.The prognostic role of mTOR and p-mTOR for survival in non-small cell lung cancer: a systematic review and meta-analysis.Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in TaiwanEML4-ALK fusion gene in Korean non-small cell lung cancerDrug development in pediatric psychiatry: current status, future trends.Benefits and Challenges with Applying Unique Molecular Identifiers in Next Generation Sequencing to Detect Low Frequency Mutations.Phospholipids as cancer biomarkers: Mass spectrometry-based analysis.Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft modelsHepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.Biospecimens and biorepositories for the community pathologist.Epigenetic Therapy in Lung Cancer - Role of microRNAs.Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusClinical and genetic features of lung squamous cell cancer in never-smokers.Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.Whole cancer genome sequencing by next-generation methods.Clinical testing for molecular targets for personalized treatment in lung cancer.Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy.Association of chromosome 19 to lung cancer genotypes and phenotypes.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology.Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model.Screening of critical genes in lung adenocarcinoma via network analysis of gene expression profile.Allele specific gain-of-function activity of p53 mutants in lung cancer cells.Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma.Impact of smoking on outcome of resected lung adenocarcinoma.A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer
P2860
Q26745424-CE86A325-67A2-46AA-9BC7-8438895297BFQ26767182-04C6BCDA-63C3-446B-96F2-630F1BD12D3DQ27853353-C1EAEECA-3BDB-4D8C-9E22-350F78B918CEQ28731874-0A1B9096-122A-4F28-BE9B-3DD2993649E7Q33947862-AE2098EA-F0F6-406E-8F3E-841C8EE2D1EDQ34328665-6669274E-AD1E-4413-9C6A-579C5B9923E2Q34404209-CF8B18F6-ADF8-4514-AA69-DD74C540FED3Q34678073-FAADD6A8-4307-42D3-9FCB-E4E68A7B206CQ34985562-46BE7BAD-4C62-4947-9D35-CA82D4DCC30CQ35095549-842FBB1B-70B4-4E96-AF71-DF5D8E37C195Q35196603-703BE549-F9CC-40AA-9450-FF9A2279F258Q35730962-2724A95F-8CC0-4284-9474-B0FF1CDE70F2Q35811894-837F9A35-609E-45DC-BCB7-E6C5C648830FQ35890662-34D60B14-D3C7-48CF-A44B-4F5FA7E6A6A8Q36045221-352558B4-AF97-4460-BFC6-EC2A33471739Q36448279-7B7A319E-CFD9-44FE-B3BF-F5C90821A44BQ36525517-0FD8C2C4-C17A-435E-AB09-933214B20711Q36920645-055EA11C-CFA9-483E-BFE4-7738EEAB21D8Q36938216-48689676-C647-4878-AFD6-D5563296D05FQ37105125-6149A64F-DFD2-437C-8238-DEC1D5786534Q37392573-6D948F3E-BD2E-4DAC-A34C-269D31CDB42CQ37392619-73AC5C9E-83DF-4CC1-AF12-AA67EF64479EQ37659109-75344F67-9F8A-48F2-A8B6-960826DFCC72Q37886990-ECA19CD3-96AD-4913-9A8D-39D4481E930AQ37932206-B6406324-3EEB-449B-B57F-5807EA59653BQ38041563-F3CFA76E-D812-4066-8434-6EDCC78C8DE3Q38253815-4C424ECB-D953-4157-B5FA-F696615BC67AQ38264378-0687F389-B62D-4F9C-B7E0-BA27431961F9Q38485902-3DB2440A-5469-4432-878E-128D1E5A2EB0Q38584814-B6C42278-C4B3-4D1C-BC1E-9DB104BBCE44Q38830254-6C2FCEF7-4314-4C6D-BBAE-1ACE8877537AQ38844605-651929FA-E8B0-4D72-A4B4-8375FCB419BCQ38902971-0BF985CD-6A23-4528-AC77-126437866D02Q39027803-6DC9F278-A15B-41B1-A552-ABD902321BAEQ39037578-9209013A-92AE-4E30-9172-D1C80620E24CQ39186842-F4C44A77-1701-43E6-8E6F-D4E9C4B50F42Q39276191-ACD97D9D-EEA5-4496-BAA8-AACD44E020A7Q39442031-ECF8343C-3B98-4155-BF3D-E8FD021EC82EQ41513953-43B22C93-DE99-45BE-B1D8-381CFC138629Q42371546-C8E0026C-577D-4F7A-964C-AD66D39BD2EE
P2860
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Driver mutations and different ...... atment of lung adenocarcinoma.
@en
Driver mutations and different ...... atment of lung adenocarcinoma.
@nl
type
label
Driver mutations and different ...... atment of lung adenocarcinoma.
@en
Driver mutations and different ...... atment of lung adenocarcinoma.
@nl
prefLabel
Driver mutations and different ...... atment of lung adenocarcinoma.
@en
Driver mutations and different ...... atment of lung adenocarcinoma.
@nl
P2093
P1476
Driver mutations and different ...... atment of lung adenocarcinoma.
@en
P2093
Antonio Russo
Corrado Ficorella
Giuseppe Bronte
Giuseppe Colucci
Laura La Paglia
Nicola Gebbia
Sergio Rizzo
Sergio Siragusa
Vincenzo Adamo
Viviana Bazan
P356
10.1016/S0305-7372(10)70016-5
P478
36 Suppl 3
P577
2010-11-01T00:00:00Z